logo

For the Inventor, By the Inventor

Cranbury, NJ, United States of America

Jonathan Laird Gross

This inventor holds 17 USPTO granted patents and 1 published patent application, primarily in CNS Agents. Top assignee: Wyeth. Active years: 2003-2011.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jonathan Laird Gross. Retrieved from https://idiyas.com/inventor/jonathan-laird-gross

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 17 

% Patents Active = 5.9

Average Co-Inventor Count = 2.8

ph-index = 2

Forward Citations = 16(Granted Patents)


Location History:

  • Robbinsville, NJ (US) (2003 - 2004)
  • Cranbury, NJ (US) (2006 - 2011)

Company Filing History:

goldMedal17 out of 1,309 
 
Wyeth
 patents

Years Active: 2003-2011

Loading Chart...
Areas of Expertise:
Histamine Antagonists
CNS Agents
Aminoalkylazole Derivatives
Dihydrobenzofuran
Chromane Derivatives
Quinoline Compounds
Antidepressants
Stereoselective Synthesis
Tricyclic Analogs
Azaheterocyclylmethyl
Glutamate Transport Inhibitors
Dioxinoquinoxaline
17 patents (USPTO):Explore Patents
1. 7935719 - N-substituted-azacyclylamines as histamine-3 antagonists (2011-05-03),
2. 7820825 - N-substituted-azacyclylamines as histamine-3 antagonists (2010-10-26),
3. 7803825 - Aminoalkylazole derivatives as histamine-3 antagonists (2010-09-28),
4. 7728155 - Dihydrobenzofuranyl alkanamines and methods for using same as cns agents (2010-06-01),
5. 7470799 - Dihydrobenzofuran derivatives and uses thereof (2008-12-30),
6. 7435837 - Dihydrobenzofuranyl alkanamine derivatives and methods for using same (2008-10-14),
7. 7368477 - Benzofuranyl alkanamine derivatives and uses thereof (2008-05-06),
8. 7365095 - Chromane and chromene derivatives and uses thereof (2008-04-29),
9. 7227023 - Quinoline 3-amino chroman derivatives (2007-06-05),
10. 7008944 - Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-Dioxino[2,3-f]quinoxaline (2006-03-07),
11. 6821981 - Azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]-quinoline as 5-HT1A antagonists (2004-11-23),
12. 6750364 - Bridged tricyclic analogs of 2-(carboxycyclopropyl)glycine as inhibitors of glutamate transport (2004-06-15),
13. 6716998 - Process for synthesis of 2-yl chroman derivatives (2004-04-06),
14. 6700001 - Process for stereoselective synthesis of 2-hydroxymethyl chromans (2004-03-02),
15. 6689905 - Stereoisomers of 3-aminotricyclo[2.2.1.0(2.6)]heptane-1,3-dicarboxylic acid (2004-02-10),

Title: The Innovative Contributions of Jonathan Laird Gross

Introduction

Jonathan Laird Gross is a prominent inventor based in Cranbury, NJ (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target the central nervous system. With a total of 17 patents to his name, Gross has established himself as a key figure in innovation.

Latest Patents

Among his latest patents are the N-substituted-azacyclylamines as histamine-3 antagonists. This invention provides a compound of formula I and outlines its use for the treatment of central nervous system disorders related to or affected by the histamine-3 receptor. The detailed specifications describe the variables involved in this innovative compound.

Career Highlights

Jonathan Laird Gross is currently associated with Wyeth, a well-known pharmaceutical company. His work at Wyeth has allowed him to focus on groundbreaking research and development in the field of medicinal chemistry. His contributions have been instrumental in advancing therapeutic options for various neurological conditions.

Collaborations

Throughout his career, Gross has collaborated with notable colleagues, including Gary Paul Stack and Hong Gao. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Jonathan Laird Gross exemplifies the spirit of innovation in the pharmaceutical industry. His extensive patent portfolio and collaborative efforts highlight his commitment to advancing medical science. His work continues to impact the treatment of central nervous system disorders, showcasing the importance of inventors in shaping the future of healthcare.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…